Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat

Neurochemical Research

Volumn 41, Issue 5, 2016, Pages 1065-1072

  Kiasalari, Zahra ^a   Khalili, Mohsen ^a   Baluchnejadmojarad, Tourandokht ^b   Roghani, Mehrdad ^a  

^a SHAHED UNIVERSITY   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 Hydroxydopamine; Apoptosis; Hesperetin; Inflammation; Oxidative stress; Parkinson s disease

Indexed keywords

CATALASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; HESPERETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; OXIDOPAMINE; PROTEIN BCL 2; HESPERIDIN; NEUROPROTECTIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; CELL LOSS; CONTROLLED STUDY; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; CORPUS STRIATUM; DRUG EFFECTS; GLIOSIS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PSYCHOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CORPUS STRIATUM; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HESPERIDIN; MALE; NEUROPROTECTIVE AGENTS; NF-KAPPA B; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; RATS, WISTAR;

EID: 84951753933     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-015-1796-6     Document Type: Article

References (50)

1. Massano J, Bhatia KP (2012) Clinical approach to Parkinson’s disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med 2:a008870
2. Jannetta PJ, Whiting DM, Fletcher LH, Hobbs JK, Brillman J, Quigley M, Fukui M, Williams R (2011) Parkinson’s disease: an inquiry into the etiology and treatment. Neurol Int 3:e7
3. Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson’s disease. Mov Disord 26:1049–1055
4. Seidl SE, Santiago JA, Bilyk H, Potashkin JA (2014) The emerging role of nutrition in Parkinson’s disease. Front Aging Neurosci 6:36
5. Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I (2007) Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 61:472–477
6. Palit S, Kar S, Sharma G, Das PK (2015) Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of ROS and activation of ASK1/JNK pathway. J Cell Physiol 230:1729–1739
7. Wang J, Zhu H, Yang Z, Liu Z (2013) Antioxidative effects of hesperetin against lead acetate-induced oxidative stress in rats. Indian J Pharmacol 45:395–398
8. Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M (2015) Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res 29:323–331
9. Yang HL, Chen SC, Senthil Kumar KJ, Yu KN, Lee Chao PD, Tsai SY, Hou YC, Hseu YC (2012) Antioxidant and anti-inflammatory potential of hesperetin metabolites obtained from hesperetin-administered rat serum: an ex vivo approach. J Agric Food Chem 60:522–532
10. Yang Z, Liu Y, Deng W, Dai J, Li F, Yuan Y, Wu Q, Zhou H, Bian Z, Tang Q (2014) Hesperetin attenuates mitochondria-dependent apoptosis in lipopolysaccharide-induced H9C2 cardiomyocytes. Mol Med Rep 9:1941–1946
11. Hwang SL, Lin JA, Shih PH, Yeh CT, Yen GC (2012) Pro-cellular survival and neuroprotection of citrus flavonoid: the actions of hesperetin in PC12 cells. Food Funct 3:1082–1090
12. Hwang SL, Shih PH, Yen GC (2012) Neuroprotective effects of citrus flavonoids. J Agric Food Chem 60:877–885
13. Antunes MS, Goes AT, Boeira SP, Prigol M, Jesse CR (2014) Protective effect of hesperidin in a model of Parkinson’s disease induced by 6-hydroxydopamine in aged mice. Nutrition 30:1415–1422
14. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
15. Choi EJ, Ahn WS (2008) Neuroprotective effects of chronic hesperetin administration in mice. Arch Pharm Res 31:1457–1462
16. Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T (2010) Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 82:279–283
17. Allbutt HN, Henderson JM (2007) Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson’s disease. J Neurosci Methods 159:195–202
18. Afshin-Majd S, Khalili M, Roghani M, Mehranmehr N, Baluchnejadmojarad T (2015) Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat. Mol Neurobiol 51:1064–1070
19. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
20. Claiborne A (1985) Catalase activity. In: Greenwald RA (ed) CRC Handbook of methods for oxygen radical research. CRC, Boca Raton, pp 283–284
21. Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205
22. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77
23. Morroni F, Tarozzi A, Sita G, Bolondi C, Zolezzi Moraga JM, Cantelli-Forti G, Hrelia P (2013) Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson’s disease. Neurotoxicology 36:63–71
24. Zare K, Eidi A, Roghani M, Rohani AH (2015) The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat. Metab Brain Dis 30:205–213
25. Healy-Stoffel M, Omar Ahmad S, Stanford JA, Levant B (2014) Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat. Brain Res 1574:113–119
26. Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–224
27. Schwarting RK, Huston JP (1997) Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology 18:689–708
28. Rainey-Smith S, Schroetke LW, Bahia P, Fahmi A, Skilton R, Spencer JP, Rice-Evans C, Rattray M, Williams RJ (2008) Neuroprotective effects of hesperetin in mouse primary neurones are independent of CREB activation. Neurosci Lett 438:29–33
29. Hwang SL, Yen GC (2011) Effect of hesperetin against oxidative stress via ER- and TrkA-mediated actions in PC12 cells. J Agric Food Chem 59:5779–5785
30. Jalali-Nadoushan M, Roghani M (2013) Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism. Brain Res 1505:68–74
31. Baranyi M, Milusheva E, Vizi ES, Sperlagh B (2006) Chromatographic analysis of dopamine metabolism in a Parkinsonian model. J Chromatogr A 1120:13–20
32. Und Halbach OVB, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Prog Neurobiol 73:151–177
33. Chen S, Le W (2006) Neuroprotective therapy in Parkinson disease. Am J Ther 13:445–457
34. Kumar B, Gupta SK, Srinivasan BP, Nag TC, Srivastava S, Saxena R, Jha KA (2013) Hesperetin rescues retinal oxidative stress, neuroinflammation and apoptosis in diabetic rats. Microvasc Res 87:65–74
35. Zhou F, Wu JY, Sun XL, Yao HH, Ding JH, Hu G (2007) Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32:2570–2580
36. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL (2006) Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197:275–283
37. Sriram K, O’Callaghan JP (2007) Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2:140–153
38. Hwang CK, Chun HS (2012) Isoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamine-induced apoptosis in dopaminergic neurons. Biosci Biotechnol Biochem 76:536–543
39. Deng W, Jiang D, Fang Y, Zhou H, Cheng Z, Lin Y, Zhang R, Zhang J, Pu P, Liu Y, Bian Z, Tang Q (2013) Hesperetin protects against cardiac remodelling induced by pressure overload in mice. J Mol Histol 44:575–585
40. Trivedi PP, Kushwaha S, Tripathi DN, Jena GB (2011) Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. Cardiovasc Toxicol 11:215–225
41. Calou I, Bandeira MA, Aguiar-Galvao W, Cerqueira G, Siqueira R, Neves KR, Brito GA, Viana G (2014) Neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertao), as evaluated by a Parkinson’s disease model in rats. Parkinsons Dis 2014:519615
42. Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M (2014) Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin—a mini-review. Life Sci 113:1–6
43. Cho J (2006) Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. Arch Pharm Res 29:699–706
44. Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic Res 39:1119–1125
45. Bagheri M, Joghataei MT, Mohseni S, Roghani M (2011) Genistein ameliorates learning and memory deficits in amyloid beta(1–40) rat model of Alzheimer’s disease. Neurobiol Learn Mem 95:270–276
46. Yin SM, Zhao D, Yu DQ, Li SL, An D, Peng Y, Xu H, Sun YP, Wang DM, Zhao J, Zhang WQ (2014) Neuroprotection by scorpion venom heat resistant peptide in 6-hydroxydopamine rat model of early-stage Parkinson’s disease. Acta Physiol Sin 66:658–666
47. Park SE, Song KI, Suh JK, Hwang D, Youn I (2015) A time-course study of behavioral and electrophysiological characteristics in a mouse model of different stages of Parkinson’s disease using 6-hydroxydopamine. Behav Brain Res 284:153–157
48. Yuan H, Liang LW, Chen ZJ, Ji HR, Wang MK, Zhang HY, Li C, Xu JY (2006) R-apomorphine protects against 6-hydroxydopamine-induced nigrostriatal damage in rat. Neurosci Bull 22:331–338
49. Richter F, Hamann M, Richter A (2008) Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice. Brain Res 1188:148–156
50. Roghani M, Behzadi G, Baluchnejadmojarad T (2002) Efficacy of elevated body swing test in the early model of Parkinson’s disease in rat. Physiol Behav 76:507–510